Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
95 hedge funds and large institutions have $317M invested in Viracta Therapeutics, Inc. Common Stock in 2014 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 32 increasing their positions, 22 reducing their positions, and 8 closing their positions.
288% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 8
131% more call options, than puts
Call options by funds: $9.11M | Put options by funds: $3.94M
81% more capital invested
Capital invested by funds: $175M → $317M (+$142M)
45% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 22
30% more funds holding
Funds holding: 73 → 95 (+22)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.5M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$10.3M |
| 3 |
PCM
Palisade Capital Management
Fort Lee,
New Jersey
|
+$7.64M |
| 4 |
O
OrbiMed
New York
|
+$6.64M |
| 5 |
HM
HealthCor Management
New York
|
+$3.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$5.69M |
| 2 |
CI
Cowen Inc
New York
|
-$3.44M |
| 3 |
DCM
Decade Capital Management
New York
|
-$2.17M |
| 4 |
Millennium Management
New York
|
-$2.06M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.56M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HCM
101
Highbridge Capital Management
New York
| – | -$186K | -186 | Closed |
|
102
Adage Capital Partners
Boston,
Massachusetts
| – | -$178K | -179 | Closed |
|
|
VKH
103
Virtu KCG Holdings
New York
| – | -$95K | -96 | Closed |
|
104
Two Sigma Investments
New York
| – | -$90K | -91 | Closed |
|
VIRX Hedge Fund Activity: Q1 2014 in Review
95 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q1 2014, worth a combined $317M — up 81% from $175M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new VIRX positions and 8 closed out — a net gain of 23 holders — while 32 added to existing stakes and 22 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $18.5M. The largest seller was BlackRock Advisors, cutting an estimated $5.69M.
- 95 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q1 2014, up from 73 in Q4 2013.
- Funds reported $317M of Viracta Therapeutics, Inc. Common Stock stock for Q1 2014, up 81% quarter-over-quarter.
- 31 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q1 2014 and 8 closed out, a net change of +23 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q1 2014 was Fidelity Investments, an estimated $18.5M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q1 2014 was BlackRock Advisors, an estimated $5.69M sold.
Based on aggregated 13F filings for Q1 2014.